Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

412

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: disitamab vedotin
DRUG: pembrolizumab
DRUG: gemcitabine
DRUG: cisplatin
DRUG: carboplatin

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

Collaborators

RemeGen Co., Ltd.
Merck Sharp & Dohme LLC